Why Injuries Heal Slower at 45 Than 25: Tendon Core Forms by Age 17
Avi Roy, a biomedical researcher, posted a thread on X on November 2 explaining why recovery slows with age. The core of the Achilles tendon barely renews after age 17, muscle stem cells activate later, and the brain's pain inhibition weakens.
Copenhagen scientists used carbon-14 dating (the "bomb pulse" from 1955–1963 nuclear tests) on 28 Achilles tendon samples. Collagen in the tendon core matched atmospheric levels from the first 17 years of life, indicating virtually no turnover in the load-bearing core after growth stops. Muscle tissue from the same donors showed fresh carbon-14, confirming muscle renews.
Roy reconciles this with studies showing ~1% daily collagen synthesis (implying a 2-month half-life): cells produce collagen, but the structural core isn't replaced. Carbon-14 dating also showed knee cartilage collagen forms in school years. A chemical age marker found intervertebral disc collagen half-life is 95 years (ages 20–40) and 215 years (ages 50–80).
Muscle repair relies on satellite cells. After one resistance session, satellite cells in fast fibers exceeded baseline at 48 hours in 22-year-olds vs 72 hours in 73-year-olds. After 2 weeks immobilization + 4 weeks training, men 61–74 regained strength but fiber size and satellite cell count did not increase; men 21–30 showed growth in both.
Pain inhibition declines with age. In Hamburg, 64 volunteers rated forearm heat pain (0–100) while a foot was in ice water. Pain ratings dropped 9.9 points (ages 20–40), 1.7 (41–60), and 1.6 (61–80); only the youngest drop was statistically significant.
Bone is an exception: 33 patients 65+ with femoral neck fractures fixed with rods healed at 94% vs 89% for younger patients, though mobility was worse.
Tendon adapts to load. In a 1-year trial, 33 people (62–70) did heavy, moderate, or no training. Patellar tendon thickened 6% (heavy), 5% (moderate), 1% (control) (borderline significance). Stretch resistance was maintained only with heavy loading; it fell in the other groups. Biopsies showed core collagen content and cross-links unchanged. Authors suggest the outer tendon region responds to loading.
🔗 Read original →
Avi Roy, a biomedical researcher, posted a thread on X on November 2 explaining why recovery slows with age. The core of the Achilles tendon barely renews after age 17, muscle stem cells activate later, and the brain's pain inhibition weakens.
Copenhagen scientists used carbon-14 dating (the "bomb pulse" from 1955–1963 nuclear tests) on 28 Achilles tendon samples. Collagen in the tendon core matched atmospheric levels from the first 17 years of life, indicating virtually no turnover in the load-bearing core after growth stops. Muscle tissue from the same donors showed fresh carbon-14, confirming muscle renews.
Roy reconciles this with studies showing ~1% daily collagen synthesis (implying a 2-month half-life): cells produce collagen, but the structural core isn't replaced. Carbon-14 dating also showed knee cartilage collagen forms in school years. A chemical age marker found intervertebral disc collagen half-life is 95 years (ages 20–40) and 215 years (ages 50–80).
Muscle repair relies on satellite cells. After one resistance session, satellite cells in fast fibers exceeded baseline at 48 hours in 22-year-olds vs 72 hours in 73-year-olds. After 2 weeks immobilization + 4 weeks training, men 61–74 regained strength but fiber size and satellite cell count did not increase; men 21–30 showed growth in both.
Pain inhibition declines with age. In Hamburg, 64 volunteers rated forearm heat pain (0–100) while a foot was in ice water. Pain ratings dropped 9.9 points (ages 20–40), 1.7 (41–60), and 1.6 (61–80); only the youngest drop was statistically significant.
Bone is an exception: 33 patients 65+ with femoral neck fractures fixed with rods healed at 94% vs 89% for younger patients, though mobility was worse.
Tendon adapts to load. In a 1-year trial, 33 people (62–70) did heavy, moderate, or no training. Patellar tendon thickened 6% (heavy), 5% (moderate), 1% (control) (borderline significance). Stretch resistance was maintained only with heavy loading; it fell in the other groups. Biopsies showed core collagen content and cross-links unchanged. Authors suggest the outer tendon region responds to loading.
🔗 Read original →
X (formerly Twitter)
Avi Roy (@agingroy) on X
Why does an injury at 45 often linger longer than the same injury at 25? Two things change, and one of them you can train.
First, some tissue is not rebuilt. Nuclear bomb tests in the 1950s and 6…
First, some tissue is not rebuilt. Nuclear bomb tests in the 1950s and 6…
Low DGLA Levels Let Senescent Cells Survive; Supplementation Triggers Ferroptotic Death
A study from Christopher Wiley's lab at Tufts University, published in Cell on November 2, reveals that the fatty acid DGLA (dihomo-gamma-linolenic acid) selectively kills senescent cells via ferroptosis.
Senescent cells accumulate with age and drive inflammation. The choice between senescence and ferroptosis — an iron-dependent form of cell death driven by lipid peroxidation — was previously unclear. Wiley's 2021 work showed senescent cells convert polyunsaturated fatty acids (PUFAs) into signaling lipids that lock in growth arrest. The new study examined what happens to these fatty acids in membranes.
In human senescent fibroblasts, membrane PUFAs increased overall, but DGLA specifically decreased. DGLA sits between FADS2 (which produces it) and FADS1 (which converts it to arachidonic acid). Across five senescence-inducing methods, the enzyme balance shifted toward FADS1, depleting DGLA.
Supplementing DGLA in culture killed senescent cells within three days via ferroptosis, sparing normal cells. Other omega-6/omega-3 fatty acids lacked this selectivity. An FADS1 inhibitor, which blocks DGLA conversion, also selectively killed senescent cells. Ferroptosis inhibitors (iron chelators, lipophilic antioxidants) rescued the cells; blockers of apoptosis or necroptosis did not. DGLA induced ferroptosis earlier in C. elegans and human cancer cells.
Senescent cells actively take up DGLA via the transporter CD36; blocking CD36 prevented death. They exist in a "sub-ferroptotic stress" state — high free iron, elevated lipoxygenase genes, and baseline membrane peroxidation — held in check by elevated GPX4.
In 22–24-month-old mice, five daily DGLA injections reduced senescence markers (β-galactosidase, p21, p16) in fat and liver after two weeks. Inflammatory genes dropped in fat. Male mice showed improved liver and kidney blood markers in cohorts with worse baseline health. Wiley is an inventor on patents for DGLA-based senolysis.
A human cohort in Kuopio, Finland (131 women, 54 men with obesity) found that an FADS1 variant (CC genotype) impairing DGLA-to-arachidonic conversion correlated with lower p21 expression in subcutaneous fat — significant in women and the combined group.
Separately, Paul Robbins' group at the University of Minnesota found conjugated fatty acids (alternating double bonds), not DGLA, induced ferroptosis in mouse senescent cells.
🔗 Read original →
A study from Christopher Wiley's lab at Tufts University, published in Cell on November 2, reveals that the fatty acid DGLA (dihomo-gamma-linolenic acid) selectively kills senescent cells via ferroptosis.
Senescent cells accumulate with age and drive inflammation. The choice between senescence and ferroptosis — an iron-dependent form of cell death driven by lipid peroxidation — was previously unclear. Wiley's 2021 work showed senescent cells convert polyunsaturated fatty acids (PUFAs) into signaling lipids that lock in growth arrest. The new study examined what happens to these fatty acids in membranes.
In human senescent fibroblasts, membrane PUFAs increased overall, but DGLA specifically decreased. DGLA sits between FADS2 (which produces it) and FADS1 (which converts it to arachidonic acid). Across five senescence-inducing methods, the enzyme balance shifted toward FADS1, depleting DGLA.
Supplementing DGLA in culture killed senescent cells within three days via ferroptosis, sparing normal cells. Other omega-6/omega-3 fatty acids lacked this selectivity. An FADS1 inhibitor, which blocks DGLA conversion, also selectively killed senescent cells. Ferroptosis inhibitors (iron chelators, lipophilic antioxidants) rescued the cells; blockers of apoptosis or necroptosis did not. DGLA induced ferroptosis earlier in C. elegans and human cancer cells.
Senescent cells actively take up DGLA via the transporter CD36; blocking CD36 prevented death. They exist in a "sub-ferroptotic stress" state — high free iron, elevated lipoxygenase genes, and baseline membrane peroxidation — held in check by elevated GPX4.
In 22–24-month-old mice, five daily DGLA injections reduced senescence markers (β-galactosidase, p21, p16) in fat and liver after two weeks. Inflammatory genes dropped in fat. Male mice showed improved liver and kidney blood markers in cohorts with worse baseline health. Wiley is an inventor on patents for DGLA-based senolysis.
A human cohort in Kuopio, Finland (131 women, 54 men with obesity) found that an FADS1 variant (CC genotype) impairing DGLA-to-arachidonic conversion correlated with lower p21 expression in subcutaneous fat — significant in women and the combined group.
Separately, Paul Robbins' group at the University of Minnesota found conjugated fatty acids (alternating double bonds), not DGLA, induced ferroptosis in mouse senescent cells.
🔗 Read original →
PubMed Central (PMC)
From the divergence of senescent cell fates to mechanisms and selectivity of senolytic drugs
Keywords: cellular senescence, senolytics, mechanisms of action, cell survival, drug discovery, ageing
"Three-Parent IVF" Shows Maternal Mitochondrial Reversion in Children
STAT compiled data from clinics in Greece, the UK, and Ukraine revealing that maternal mitochondria — which the technique aims to replace — have reappeared in several children born via mitochondrial replacement therapy (MRT).
Mitochondria carry their own DNA, inherited maternally; mutations cause severe diseases. MRT transfers the nuclear DNA from a mother's egg or embryo into a donor egg with healthy mitochondria. However, trace maternal mitochondria tag along with the nucleus. In 2016, Shoukhrat Mitalipov's group showed that while donor DNA exceeded 99% in embryos, it gradually lost ground to maternal DNA in derived stem cell lines, a phenomenon dubbed "reversion."
In the Greek infertility trial, one of six children saw maternal mitochondria rise from <1% in the embryo to 30–60% at birth. In Newcastle, UK, where MRT treats mitochondrial disease, three of eight children showed 5%, 12%, and 16% mutant maternal mitochondria in blood. Ukraine's Nadiya clinic provided unpublished data: two of six children exhibited reversion up to 12% and 72%.
Embryologist Jacques Cohen argues reversion is less concerning for infertility — where mothers lack pathogenic mutations — but urges a moratorium for mitochondrial disease until reversion risk is minimized. Bioethicist Guido Pennings proposes testing first in infertile couples without mutations to study reversion safely.
STAT found clinics marketing MRT to older women, claiming young mitochondria aid development. Nadiya embryologist Pavel Mazur transferred nuclei from 19 women aged 36–44 into young donor eggs; only one yielded a chromosomally normal embryo. Conversely, transferring young donor nuclei into patient eggs yielded 40% usable embryos with 70% normal chromosomes — suggesting nuclear DNA damage, not mitochondrial age, drives failure.
In Ghent, Dominik Stoop sought approval for three patient groups. Belgian authorities approved two: mitochondrial disease and oocyte/embryo maturation arrest. The third — advanced maternal age — was rejected. Stoop noted the disease group, seen as least ethically problematic, may be the riskiest.
Mary Herbert (Monash University, formerly Newcastle) cites clinical data showing pathogenic transmission dropped 75–100%, with mutant loads staying below the 50% symptom threshold. Her Australian team is preparing a trial to track mutant load stability over time and across tissues. STAT, November 3
🔗 Read original →
STAT compiled data from clinics in Greece, the UK, and Ukraine revealing that maternal mitochondria — which the technique aims to replace — have reappeared in several children born via mitochondrial replacement therapy (MRT).
Mitochondria carry their own DNA, inherited maternally; mutations cause severe diseases. MRT transfers the nuclear DNA from a mother's egg or embryo into a donor egg with healthy mitochondria. However, trace maternal mitochondria tag along with the nucleus. In 2016, Shoukhrat Mitalipov's group showed that while donor DNA exceeded 99% in embryos, it gradually lost ground to maternal DNA in derived stem cell lines, a phenomenon dubbed "reversion."
In the Greek infertility trial, one of six children saw maternal mitochondria rise from <1% in the embryo to 30–60% at birth. In Newcastle, UK, where MRT treats mitochondrial disease, three of eight children showed 5%, 12%, and 16% mutant maternal mitochondria in blood. Ukraine's Nadiya clinic provided unpublished data: two of six children exhibited reversion up to 12% and 72%.
Embryologist Jacques Cohen argues reversion is less concerning for infertility — where mothers lack pathogenic mutations — but urges a moratorium for mitochondrial disease until reversion risk is minimized. Bioethicist Guido Pennings proposes testing first in infertile couples without mutations to study reversion safely.
STAT found clinics marketing MRT to older women, claiming young mitochondria aid development. Nadiya embryologist Pavel Mazur transferred nuclei from 19 women aged 36–44 into young donor eggs; only one yielded a chromosomally normal embryo. Conversely, transferring young donor nuclei into patient eggs yielded 40% usable embryos with 70% normal chromosomes — suggesting nuclear DNA damage, not mitochondrial age, drives failure.
In Ghent, Dominik Stoop sought approval for three patient groups. Belgian authorities approved two: mitochondrial disease and oocyte/embryo maturation arrest. The third — advanced maternal age — was rejected. Stoop noted the disease group, seen as least ethically problematic, may be the riskiest.
Mary Herbert (Monash University, formerly Newcastle) cites clinical data showing pathogenic transmission dropped 75–100%, with mutant loads staying below the 50% symptom threshold. Her Australian team is preparing a trial to track mutant load stability over time and across tissues. STAT, November 3
🔗 Read original →
STAT
‘Three-parent IVF’ was supposed to prevent mitochondrial disease. Studies are raising doubts
Scientists and ethicists are rethinking the potential risks and benefits of a technology to prevent babies from inheriting rare mitochondrial diseases.
Castrating Adult Male Mice Extends Lifespan More Than Pre-Pubertal Castration (Preprint)
James Nelson's group at the University of Texas Health San Antonio castrated male mice at 20 days (pre-puberty), 60 days (post-puberty), and 240 days (adulthood). Median lifespan reached 841, 887, and 937 days respectively, versus 705 days for sham-operated controls. The preprint appeared on bioRxiv, Oct 24, 2026; a Science news piece followed on Nov 2.
Men live shorter lives than women almost everywhere; in the US in 2024 the gap was 4.9 years. Testes are a prime suspect: a Korean genealogy of 81 eunuchs showed they lived 14–19 years longer than intact men of similar status, though another researcher disputed the records' reliability. In genetically heterogeneous UM-HET3 mice, females consistently outlive males. In a 2023 experiment, Nelson's group castrated such males pre-puberty, raising median lifespan from 771 to 850 days, matching females. The remaining question: from what age do testicular factors — hormones and other secretions — cause harm?
If the pubertal hormone surge sets the damage, surgery at 60 days (after puberty) would be too late; if harm accumulates from youth, surgery at 240 days (before male mortality rises) would be too late. Controls lived shorter than in past studies: median 705 days vs 771. The authors note this may inflate percentage gains: castration at 240 days added 32.9% to 705 days, but only 21.5% to 771. Surgery at 60 days did not differ significantly from 20 days; the authors conclude the pubertal hormone surge does not shorten male life.
From roughly 240 days, mortality in intact males rises, and surgery at this age halted that rise immediately: on the preprint's survival curve, no mouse in this group died for about a year post-operation. Surgery at 240 days worked, so testicular factors act fast, and elevated male mortality depends on their continuous presence. Mice retaining testes until 240 days died less often in late life than those castrated at 20 days, suggesting testes may be beneficial before 240 days. The authors checked for a "reserve" of resilience, but grip strength and frailty indices were no better than in earlier-castrated mice.
A zoo-data analysis in Nature found pre-pubertal castration extended life more than later castration; the preprint authors say their data contradict the "earlier is better" model. The first author of that analysis, Michael Garratt (University of Otago), uninvolved in the mouse study, commented: "I am convinced that late-life castration causes a robust increase in survival." If harmful testicular factors are identified, "castration mimetics" — interventions giving the same lifespan gain without surgery — become possible. Since surgery helps at 240 days, the authors estimate these factors can be blocked in adulthood, preserving any early-life benefit.
Per a review by Nelson's group, 11 of 13 lifespan-extending compounds in the ITP program show stronger effects in males or work only in males. The preprint authors speculate some may suppress testicular harm, and propose testing compounds in males with and without testes to find those acting via testicular factors.
🔗 Read original →
James Nelson's group at the University of Texas Health San Antonio castrated male mice at 20 days (pre-puberty), 60 days (post-puberty), and 240 days (adulthood). Median lifespan reached 841, 887, and 937 days respectively, versus 705 days for sham-operated controls. The preprint appeared on bioRxiv, Oct 24, 2026; a Science news piece followed on Nov 2.
Men live shorter lives than women almost everywhere; in the US in 2024 the gap was 4.9 years. Testes are a prime suspect: a Korean genealogy of 81 eunuchs showed they lived 14–19 years longer than intact men of similar status, though another researcher disputed the records' reliability. In genetically heterogeneous UM-HET3 mice, females consistently outlive males. In a 2023 experiment, Nelson's group castrated such males pre-puberty, raising median lifespan from 771 to 850 days, matching females. The remaining question: from what age do testicular factors — hormones and other secretions — cause harm?
If the pubertal hormone surge sets the damage, surgery at 60 days (after puberty) would be too late; if harm accumulates from youth, surgery at 240 days (before male mortality rises) would be too late. Controls lived shorter than in past studies: median 705 days vs 771. The authors note this may inflate percentage gains: castration at 240 days added 32.9% to 705 days, but only 21.5% to 771. Surgery at 60 days did not differ significantly from 20 days; the authors conclude the pubertal hormone surge does not shorten male life.
From roughly 240 days, mortality in intact males rises, and surgery at this age halted that rise immediately: on the preprint's survival curve, no mouse in this group died for about a year post-operation. Surgery at 240 days worked, so testicular factors act fast, and elevated male mortality depends on their continuous presence. Mice retaining testes until 240 days died less often in late life than those castrated at 20 days, suggesting testes may be beneficial before 240 days. The authors checked for a "reserve" of resilience, but grip strength and frailty indices were no better than in earlier-castrated mice.
A zoo-data analysis in Nature found pre-pubertal castration extended life more than later castration; the preprint authors say their data contradict the "earlier is better" model. The first author of that analysis, Michael Garratt (University of Otago), uninvolved in the mouse study, commented: "I am convinced that late-life castration causes a robust increase in survival." If harmful testicular factors are identified, "castration mimetics" — interventions giving the same lifespan gain without surgery — become possible. Since surgery helps at 240 days, the authors estimate these factors can be blocked in adulthood, preserving any early-life benefit.
Per a review by Nelson's group, 11 of 13 lifespan-extending compounds in the ITP program show stronger effects in males or work only in males. The preprint authors speculate some may suppress testicular harm, and propose testing compounds in males with and without testes to find those acting via testicular factors.
🔗 Read original →
Science
Castration extends life span, but in a surprising way, mouse study suggests
Scientists say work could help identify “castration mimetics” that boost longevity
Revel Pharmaceuticals Co-Founder Chooses Enzymatic Protein Repair Over Cellular Reprogramming
Aaron Cravens explained on the November 3 Free Radicals podcast how Revel selects damage targets for repair and why he believes cellular reprogramming — the attempt to revert cells to a youthful state — faces a fundamental delivery barrier.
Collagen and other structural proteins persist for decades while surrounding cells turnover, accumulating chemical damage. Cravens calls this "rust" and selects targets by asking: "What is in old tissue that isn't in young tissue? And if it's in old tissue and not in young tissue — not counting wisdom — we want to get rid of it." His hypothesis: removing all damage distinguishing old from young should restore a youthful state.
Revel largely ignores cellular biology as too complex. Damage has known chemical structures and accumulates linearly with age, whereas senescent cells exist even in the young. Cravens cites the cautionary example of senolytics: senescent cells may be needed for wound healing. Reprogramming, he argues, hits a delivery wall: rejuvenating fibroblasts requires reaching over 90% of them, but delivering DNA-based technologies is difficult.
Revel's first target is carboxymethyllysine (CML), a lysine modified by reactions with sugars and fats. Known for ~40 years, Cravens expected success within six years. CML blocks collagen lysines used for cell binding and triggers systemic inflammation in mice. In humans, CML correlates with mortality: an Italian study of 1,013 people over 65 found the top tertile of plasma CML had a 2.1x higher risk of cardiovascular death over six years (Nature Communications, July 14).
Cravens posits that regeneration weakens because damage has "rusted it in place." Reprogramming proponents hope engineered cells will restore this capacity. Instead, Revel mimics lysosomal storage disease therapy: supplying missing enzymes to clear accumulated waste. For damage accumulating over decades, the body lacks enzymes because evolution didn't require post-reproductive longevity.
On July 14, Revel published in Nature Communications on CMLase, an engineered bacterial enzyme. It converted CML back to lysine: on donor tissue slices, CML staining dropped >70% in a 75-year-old's aorta and >55% in a 74-year-old's skin, reaching levels below a 31-year-old's skin. Cravens aims to apply CMLase first for diabetic retinopathy, kidney disease, and skin aging, hoping for topical use within a year. He plans 4–6 drugs against different damage types and envisions synergy with reprogramming if a working cocktail emerges.
🔗 Read original →
Aaron Cravens explained on the November 3 Free Radicals podcast how Revel selects damage targets for repair and why he believes cellular reprogramming — the attempt to revert cells to a youthful state — faces a fundamental delivery barrier.
Collagen and other structural proteins persist for decades while surrounding cells turnover, accumulating chemical damage. Cravens calls this "rust" and selects targets by asking: "What is in old tissue that isn't in young tissue? And if it's in old tissue and not in young tissue — not counting wisdom — we want to get rid of it." His hypothesis: removing all damage distinguishing old from young should restore a youthful state.
Revel largely ignores cellular biology as too complex. Damage has known chemical structures and accumulates linearly with age, whereas senescent cells exist even in the young. Cravens cites the cautionary example of senolytics: senescent cells may be needed for wound healing. Reprogramming, he argues, hits a delivery wall: rejuvenating fibroblasts requires reaching over 90% of them, but delivering DNA-based technologies is difficult.
Revel's first target is carboxymethyllysine (CML), a lysine modified by reactions with sugars and fats. Known for ~40 years, Cravens expected success within six years. CML blocks collagen lysines used for cell binding and triggers systemic inflammation in mice. In humans, CML correlates with mortality: an Italian study of 1,013 people over 65 found the top tertile of plasma CML had a 2.1x higher risk of cardiovascular death over six years (Nature Communications, July 14).
Cravens posits that regeneration weakens because damage has "rusted it in place." Reprogramming proponents hope engineered cells will restore this capacity. Instead, Revel mimics lysosomal storage disease therapy: supplying missing enzymes to clear accumulated waste. For damage accumulating over decades, the body lacks enzymes because evolution didn't require post-reproductive longevity.
On July 14, Revel published in Nature Communications on CMLase, an engineered bacterial enzyme. It converted CML back to lysine: on donor tissue slices, CML staining dropped >70% in a 75-year-old's aorta and >55% in a 74-year-old's skin, reaching levels below a 31-year-old's skin. Cravens aims to apply CMLase first for diabetic retinopathy, kidney disease, and skin aging, hoping for topical use within a year. He plans 4–6 drugs against different damage types and envisions synergy with reprogramming if a working cocktail emerges.
🔗 Read original →
Nature
Reversal of protein chemical aging by enzymatic deglycation
Nature Communications - Advanced glycation end products (AGEs) in proteins, a hallmark of aging, are considered irreversible. Here, authors report the development of CMLase - an enzyme that...
Kurzweil vs. Hinton: Same Age, Different Outlook
In our chat, someone suggested Geoffrey Hinton's alarmism stems from his age. Consider Ray Kurzweil, who is currently the same 78 years old as Hinton. Notice the difference?
🔗 Source: @solid_state_humanity
In our chat, someone suggested Geoffrey Hinton's alarmism stems from his age. Consider Ray Kurzweil, who is currently the same 78 years old as Hinton. Notice the difference?
🔗 Source: @solid_state_humanity
Telegram
Solid State Humanity
В нашем чате предположили, что паникёрство Хинтона обусловлено его возрастом. Вот вам Курцвэйл, которому сейчас те же самые 78 лет, что и Хинтону. Чувствуете разницу?
George Murphy Parses First ER-100 Gene Therapy Data: Vision Benefit, Tissue Rejuvenation, and Healthspan Extension Require Different Evidence
On November 2, George Murphy, co-founder of the Boston University Center for Regenerative Medicine, analyzed the initial ER-100 data on The ReProgram podcast. This gene therapy transiently induces retinal cells to produce three proteins to restore a more youthful gene expression pattern.
On October 8, Life Biosciences reported that in a Phase 1 safety trial, two of three glaucoma patients showed improved visual field test results at 56 days. Murphy sees grounds for further study. If future trials confirm sustained vision improvement, he argues for distinguishing three claims.
First, clinical benefit: the patient sees better or loses vision more slowly. Second, tissue rejuvenation: this requires linking the intervention, biological changes, and improved tissue function, since protection, compensation, or better function of surviving cells could also drive improvement. Glaucoma specialist James Tsai, uninvolved in the trial, raised a similar point in Business Insider: the therapy may have merely enhanced existing electrical signals in patients with residual vision.
Third, healthspan extension: the heart, immune system, and brain pose distinct delivery challenges, biology, endpoints, and risks, demanding separate, larger studies.
The visual field test maps light sensitivity: the patient fixates centrally while the device detects the dimmest visible flash at each point (threshold in decibels). The release states that for each of the two responders, at least 28% of test points improved by more than 4 decibels.
Murphy highlights alternative explanations. Practice effects are documented in glaucoma suspects; a randomly low baseline makes the next test appear better without treatment. The registry lists the trial as open-label — clinicians and participants know the treatment assignment — and expectations can influence responses on an attention-dependent test. Each participant is compared to their own baseline. With many test points and visits, some improvements may be chance findings. Points within one eye belong to a single biological system: "Several improved test points in one eye do not equal several independent patients."
Other endpoints recorded in the registry at Day 56 and Day 112 — such as visual acuity (letter reading) and retinal electrical response — could corroborate the field improvement. Doxycycline, taken for 56 days, activates protein production; the Day 112 measurement will show whether improvement persists after shutdown. Murphy notes: "Turning off production of a biological factor and reversing what it has already changed are different tasks."
For Murphy, a useful therapy makes tissue better at its job with acceptable, durable safety; molecular analyses showing a "younger" tissue state may only help explain the result. He wants longitudinal per-participant data; comparison with a control group and independent adjudication; benefit noticeable to the patient; and replication in larger, multi-center cohorts. In his episode description he writes: "A treatment can be a major medical advance without proving that aging has been reversed."
🔗 Read original →
On November 2, George Murphy, co-founder of the Boston University Center for Regenerative Medicine, analyzed the initial ER-100 data on The ReProgram podcast. This gene therapy transiently induces retinal cells to produce three proteins to restore a more youthful gene expression pattern.
On October 8, Life Biosciences reported that in a Phase 1 safety trial, two of three glaucoma patients showed improved visual field test results at 56 days. Murphy sees grounds for further study. If future trials confirm sustained vision improvement, he argues for distinguishing three claims.
First, clinical benefit: the patient sees better or loses vision more slowly. Second, tissue rejuvenation: this requires linking the intervention, biological changes, and improved tissue function, since protection, compensation, or better function of surviving cells could also drive improvement. Glaucoma specialist James Tsai, uninvolved in the trial, raised a similar point in Business Insider: the therapy may have merely enhanced existing electrical signals in patients with residual vision.
Third, healthspan extension: the heart, immune system, and brain pose distinct delivery challenges, biology, endpoints, and risks, demanding separate, larger studies.
The visual field test maps light sensitivity: the patient fixates centrally while the device detects the dimmest visible flash at each point (threshold in decibels). The release states that for each of the two responders, at least 28% of test points improved by more than 4 decibels.
Murphy highlights alternative explanations. Practice effects are documented in glaucoma suspects; a randomly low baseline makes the next test appear better without treatment. The registry lists the trial as open-label — clinicians and participants know the treatment assignment — and expectations can influence responses on an attention-dependent test. Each participant is compared to their own baseline. With many test points and visits, some improvements may be chance findings. Points within one eye belong to a single biological system: "Several improved test points in one eye do not equal several independent patients."
Other endpoints recorded in the registry at Day 56 and Day 112 — such as visual acuity (letter reading) and retinal electrical response — could corroborate the field improvement. Doxycycline, taken for 56 days, activates protein production; the Day 112 measurement will show whether improvement persists after shutdown. Murphy notes: "Turning off production of a biological factor and reversing what it has already changed are different tasks."
For Murphy, a useful therapy makes tissue better at its job with acceptable, durable safety; molecular analyses showing a "younger" tissue state may only help explain the result. He wants longitudinal per-participant data; comparison with a control group and independent adjudication; benefit noticeable to the patient; and replication in larger, multi-center cohorts. In his episode description he writes: "A treatment can be a major medical advance without proving that aging has been reversed."
🔗 Read original →
PubMed Central (PMC)
A longevity‐specific bank of induced pluripotent stem cells from centenarians and their offspring
Centenarians provide a unique lens through which to study longevity, healthy aging, and resiliency. Moreover, models of human aging and resilience to disease that allow for the testing of potential interventions are virtually non‐existent. We ...
Tiny Magnetic Beads Enable Precise Bionic Limb Control
A new technique called magnetomicrometry uses tiny magnetic beads implanted directly into muscle tissue to control bionic prostheses. This bypasses the limitations of surface electrodes, which suffer from signal noise, sweat interference, and signal decay over time.
Researchers implanted up to four pairs of 3-millimeter beads — made from a neodymium-iron-boron alloy and coated in gold and biocompatible Parylene C — into the ankle muscles of three below-knee amputees. External sensors tracked the beads' magnetic fields through up to 6 centimeters of tissue, measuring physical distance changes during muscle contraction and extension.
Participants controlled a virtual cursor using muscle effort, allowing direct comparison of surface EMG, implanted electrodes, and magnetomicrometry. The magnetic approach delivered significantly more stable, cleaner, and precise control because it measures actual mechanical movement rather than noisy electrical activity.
The team is now advancing to expanded clinical trials to test the implants within full robotic leg prostheses. Science Robotics, July 2024
🔗 Read original →
A new technique called magnetomicrometry uses tiny magnetic beads implanted directly into muscle tissue to control bionic prostheses. This bypasses the limitations of surface electrodes, which suffer from signal noise, sweat interference, and signal decay over time.
Researchers implanted up to four pairs of 3-millimeter beads — made from a neodymium-iron-boron alloy and coated in gold and biocompatible Parylene C — into the ankle muscles of three below-knee amputees. External sensors tracked the beads' magnetic fields through up to 6 centimeters of tissue, measuring physical distance changes during muscle contraction and extension.
Participants controlled a virtual cursor using muscle effort, allowing direct comparison of surface EMG, implanted electrodes, and magnetomicrometry. The magnetic approach delivered significantly more stable, cleaner, and precise control because it measures actual mechanical movement rather than noisy electrical activity.
The team is now advancing to expanded clinical trials to test the implants within full robotic leg prostheses. Science Robotics, July 2024
🔗 Read original →
Nature
A wireless magnetic implant system for continuous neuromuscular sensing
Nature Sensors - A skin-mounted magnetometer array that wirelessly tracks implanted magnetic beads enables precise neuromuscular sensing and neuroprosthetic control that match or exceed those...
Cyberpunk Reality: Hackers Target French Blood Bank Freezers
On the night of November 1–2, 2026, hackers breached Coolworld, the vendor managing freezers for the French Blood Establishment (Établissement français du sang). They remotely altered temperature settings for donor plasma storage from the required -30°C to 110°C.
Fortunately, an on-duty technician spotted the anomaly overnight. Staff regained control before critical transfusion reserves could thaw or spoil. While the 110°C figure was alarming, it was merely a controller command, not the actual chamber temperature. Fresh-frozen plasma must be stored at -25°C or below, making the rapid staff response decisive.
No official details on the intrusion method have been released. However, security experts reiterate that connecting industrial refrigeration directly to the open internet is reckless — a vulnerability hospitals and suppliers now pay for with risks to medical stockpiles.
🔗 Source: @solid_state_humanity
On the night of November 1–2, 2026, hackers breached Coolworld, the vendor managing freezers for the French Blood Establishment (Établissement français du sang). They remotely altered temperature settings for donor plasma storage from the required -30°C to 110°C.
Fortunately, an on-duty technician spotted the anomaly overnight. Staff regained control before critical transfusion reserves could thaw or spoil. While the 110°C figure was alarming, it was merely a controller command, not the actual chamber temperature. Fresh-frozen plasma must be stored at -25°C or below, making the rapid staff response decisive.
No official details on the intrusion method have been released. However, security experts reiterate that connecting industrial refrigeration directly to the open internet is reckless — a vulnerability hospitals and suppliers now pay for with risks to medical stockpiles.
🔗 Source: @solid_state_humanity
Telegram
Solid State Humanity
Новости киберпанка
В ночь с 1 на 2 ноября 2026 года хакеры взломали компанию Coolworld, которая обслуживает холодильники Французского учреждения крови, и удаленно выкрутили настройки в морозилках для хранения донорской плазмы с положенных -30°C до безумных…
В ночь с 1 на 2 ноября 2026 года хакеры взломали компанию Coolworld, которая обслуживает холодильники Французского учреждения крови, и удаленно выкрутили настройки в морозилках для хранения донорской плазмы с положенных -30°C до безумных…
Review Proposes Testing "Aging as a Non-Healing Wound" Hypothesis via Tissue Repair Dynamics
On October 10, Piotr Paweł Chmielewski and Bartłomiej Strzelec from Wrocław Medical University published a review in International Journal of Molecular Sciences. They argue that some age-related dysfunction arises when tissue repair stalls midway: dead cells persist and inflammation fails to resolve.
The "aging as a non-healing wound" hypothesis was proposed in 2025 by Mikołaj Ogródnik in Nature Communications. He observed that aging skin, liver, and brain retain inflammation and senescent cells — which do not divide but secrete inflammatory factors — mirroring the inflammatory phase of wound healing. Ogródnik suggested repair becomes trapped in this phase.
Chmielewski and Strzelec propose separately quantifying tissue damage burden, repair capacity, and residual functional loss to distinguish weak repair from excessive damage. Tissue resilience, they argue, is revealed by the response to a standardized injury: peak response, decay speed, and completeness of recovery.
Such measurement in humans was described in 2020 by Derek Gilroy's group at University College London in Nature Immunology. Volunteers aged 18–40 and over 65 received cantharidin blisters on the forearm. At day 1, neutrophil counts were equal; by day 3, counts fell in the young but remained elevated in the elderly. Elderly macrophages (clearance cells) poorly engulfed dying cells due to elevated p38 enzyme activity depleting the TIM-4 receptor. Eleven elderly participants took losmapimod, a p38 inhibitor, prior to blistering. In treated samples, TIM-4 returned and fewer dying neutrophils accumulated, though neutrophil influx and two inflammatory proteins were unchanged.
A Stanford University experiment in Science demonstrated the role of clearance failure in mouse organ aging. Mice lacking the EP2 receptor in tissue macrophages — which normally inhibits clearance of senescent neutrophils — maintained clearance, memory, and muscle mass into old age.
Treatment choice, per the review, depends on the primary measurable repair defect (excess damage, senescent cells, or clearance failure) and timing: suppressing early protective responses may hinder repair, while correcting chronic responses may help. Senolytics — drugs targeting senescent cells — "induce death of susceptible senescent cells but do not themselves remove the resulting cellular debris," the authors write: with weak clearance, dead cell remnants and secondary inflammatory signals may replace living senescent cells.
The hypothesis weakens if a prolonged damage response fails to predict functional decline; if recovery speed adds no prognostic value beyond epigenetic clocks (DNA methylation-based biological age) and similar measures; or if a drug that hits its target and corrects a repair defect repeatedly fails to improve tissue function. Trials, the review states, must enroll people with confirmed repair defects and judge success by restored tissue function. Reduced inflammatory markers and youthful molecular age remain intermediate endpoints: in a Harvard Medical School preprint, gene-activity clocks rated mouse intestinal epithelium at peak healing as younger than undamaged tissue.
🔗 Read original →
On October 10, Piotr Paweł Chmielewski and Bartłomiej Strzelec from Wrocław Medical University published a review in International Journal of Molecular Sciences. They argue that some age-related dysfunction arises when tissue repair stalls midway: dead cells persist and inflammation fails to resolve.
The "aging as a non-healing wound" hypothesis was proposed in 2025 by Mikołaj Ogródnik in Nature Communications. He observed that aging skin, liver, and brain retain inflammation and senescent cells — which do not divide but secrete inflammatory factors — mirroring the inflammatory phase of wound healing. Ogródnik suggested repair becomes trapped in this phase.
Chmielewski and Strzelec propose separately quantifying tissue damage burden, repair capacity, and residual functional loss to distinguish weak repair from excessive damage. Tissue resilience, they argue, is revealed by the response to a standardized injury: peak response, decay speed, and completeness of recovery.
Such measurement in humans was described in 2020 by Derek Gilroy's group at University College London in Nature Immunology. Volunteers aged 18–40 and over 65 received cantharidin blisters on the forearm. At day 1, neutrophil counts were equal; by day 3, counts fell in the young but remained elevated in the elderly. Elderly macrophages (clearance cells) poorly engulfed dying cells due to elevated p38 enzyme activity depleting the TIM-4 receptor. Eleven elderly participants took losmapimod, a p38 inhibitor, prior to blistering. In treated samples, TIM-4 returned and fewer dying neutrophils accumulated, though neutrophil influx and two inflammatory proteins were unchanged.
A Stanford University experiment in Science demonstrated the role of clearance failure in mouse organ aging. Mice lacking the EP2 receptor in tissue macrophages — which normally inhibits clearance of senescent neutrophils — maintained clearance, memory, and muscle mass into old age.
Treatment choice, per the review, depends on the primary measurable repair defect (excess damage, senescent cells, or clearance failure) and timing: suppressing early protective responses may hinder repair, while correcting chronic responses may help. Senolytics — drugs targeting senescent cells — "induce death of susceptible senescent cells but do not themselves remove the resulting cellular debris," the authors write: with weak clearance, dead cell remnants and secondary inflammatory signals may replace living senescent cells.
The hypothesis weakens if a prolonged damage response fails to predict functional decline; if recovery speed adds no prognostic value beyond epigenetic clocks (DNA methylation-based biological age) and similar measures; or if a drug that hits its target and corrects a repair defect repeatedly fails to improve tissue function. Trials, the review states, must enroll people with confirmed repair defects and judge success by restored tissue function. Reduced inflammatory markers and youthful molecular age remain intermediate endpoints: in a Harvard Medical School preprint, gene-activity clocks rated mouse intestinal epithelium at peak healing as younger than undamaged tissue.
🔗 Read original →
PubMed Central (PMC)
Tumors: Wounds that do not heal--Redux
Similarities between tumors and the inflammatory response associated with wound healing have been recognized for more than 150 years and continue to intrigue. Some years ago, based on our then recent discovery of vascular permeability factor ...
Zoltan Istvan Warns Transhumanism Is Drifting Left
Zoltan Istvan recently published an article titled "Transhumanism is Under Siege from Socialism." In interviews he has complained that the movement is tilting sharply leftward, noting that most young transhumanists now lean socialist while the libertarian/capitalist faction he represents has become a minority. He says he is trying to "save" transhumanism from Silicon Valley "leftwingism" and socialist ideas.
The meme references Pinochet's "helicopter" tactics against leftists, but I urge everyone not to harm left‑leaning transhumanists. They are indeed pulling the ideology left, yet transhumanism is already small and diverse. Instead, let's explain that everyone benefits not from redistribution or reducing economic inequality, but from treating inequality as a strictly biological problem — one solved by engineering.
🔗 Read original →
Zoltan Istvan recently published an article titled "Transhumanism is Under Siege from Socialism." In interviews he has complained that the movement is tilting sharply leftward, noting that most young transhumanists now lean socialist while the libertarian/capitalist faction he represents has become a minority. He says he is trying to "save" transhumanism from Silicon Valley "leftwingism" and socialist ideas.
The meme references Pinochet's "helicopter" tactics against leftists, but I urge everyone not to harm left‑leaning transhumanists. They are indeed pulling the ideology left, yet transhumanism is already small and diverse. Instead, let's explain that everyone benefits not from redistribution or reducing economic inequality, but from treating inequality as a strictly biological problem — one solved by engineering.
🔗 Read original →
Transhumanist Media
Transhumanism is Under Siege from Socialism
Transhumanism, once a libertarian-driven movement, is increasingly influenced by the left. The movement, now expanding with advancements in AI and bioengineering, faces debates over accessibility, social inequality, and the role of capitalism in ensuring…
Sam Altman Says AI Now "Mostly Smarter" Than Top Scientists, Warns Against Ceding Control
At the ADIPEC energy conference in Abu Dhabi on November 2, OpenAI CEO Sam Altman stated that AI has recently surpassed the capabilities of the world's leading researchers. "Earlier this year... AI was mostly not as smart as our smartest scientists, and now it is mostly smarter than them," he told *The National*, noting capabilities remain uneven. He stressed that human judgment and accountability must remain central: "We think it is absolutely critical that humans remain in control of the future... There should be no ceding of control to AI."
In his keynote, Altman revealed that 10,000 autonomous agents — copies of an unreleased model — collaborated for ~88 hours to prove a Millennium Prize problem, costing roughly $10 million. The agents operated in a fully decentralized manner with no hierarchy, selecting directions and learning from each other. While Altman did not name the problem, the details match OpenAI's September 8 announcement regarding the Navier-Stokes equations, which describe fluid dynamics. The agents proved a "blowup" (infinite velocity in finite time) for a flow driven by an external force.
The Clay Mathematics Institute called the problem "apparently solved" on September 11, though mathematician Luis Silvestre told Scientific American the core challenge — flow without external force — remains open: "The Clay problem is solved, but the main problem about Navier-Stokes is not." OpenAI confirmed researchers directed the agents, providing a starting proof for frictionless fluid found by ~100 prior agents.
Meanwhile, UAE state oil giant ADNOC announced a partnership with OpenAI and G42 to deploy the OpenAI Frontier platform for autonomous agents, starting with reservoir development planning. ADNOC emphasized that significant decisions will stay under human expert supervision.
🔗 Read original →
At the ADIPEC energy conference in Abu Dhabi on November 2, OpenAI CEO Sam Altman stated that AI has recently surpassed the capabilities of the world's leading researchers. "Earlier this year... AI was mostly not as smart as our smartest scientists, and now it is mostly smarter than them," he told *The National*, noting capabilities remain uneven. He stressed that human judgment and accountability must remain central: "We think it is absolutely critical that humans remain in control of the future... There should be no ceding of control to AI."
In his keynote, Altman revealed that 10,000 autonomous agents — copies of an unreleased model — collaborated for ~88 hours to prove a Millennium Prize problem, costing roughly $10 million. The agents operated in a fully decentralized manner with no hierarchy, selecting directions and learning from each other. While Altman did not name the problem, the details match OpenAI's September 8 announcement regarding the Navier-Stokes equations, which describe fluid dynamics. The agents proved a "blowup" (infinite velocity in finite time) for a flow driven by an external force.
The Clay Mathematics Institute called the problem "apparently solved" on September 11, though mathematician Luis Silvestre told Scientific American the core challenge — flow without external force — remains open: "The Clay problem is solved, but the main problem about Navier-Stokes is not." OpenAI confirmed researchers directed the agents, providing a starting proof for frictionless fluid found by ~100 prior agents.
Meanwhile, UAE state oil giant ADNOC announced a partnership with OpenAI and G42 to deploy the OpenAI Frontier platform for autonomous agents, starting with reservoir development planning. ADNOC emphasized that significant decisions will stay under human expert supervision.
🔗 Read original →
Scientific American
Did OpenAI solve the wrong Navier-Stokes problem?
OpenAI’s proof seems eligible for a $1-million prize—but only by using a controversial loophole
Dog Aging Project Links LINE-1 Transposons and IGF-1 to Size-Related Aging Differences
On November 2, the Longevity for Dogs podcast released a conversation between Dog Aging Institute president Matt Kaeberlein and Noah Snyder-Mackler of Arizona State University. Snyder-Mackler is senior author of a Science paper from October 8 that used DNA methylation in blood from 894 dogs in the Dog Aging Project to estimate aging rates.
Larger dogs live shorter lives. To test whether this difference appears at the cellular level, the authors used epigenetic clocks — algorithms that estimate age from DNA methylation, chemical marks that switch genes on and off. On average, clocks showed large dogs as older than their chronological age, and the gap predicted mortality: the larger the discrepancy, the higher the risk of dying within two years. Marks were measured in blood immune cells; other organs may age differently.
Evan MacLean of the Dog Aging Project noted that memory and cognition decline at a similar pace across all sizes: "large dogs may simply die before any cognitive disorder develops."
To find the mechanism, the authors compared genome-wide methylation loss with age. Large dogs lose marks faster overall, most notably in LINE-1 transposons — "jumping" DNA segments that copy and insert themselves elsewhere. Methylation keeps them silenced, and "young" LINE-1 copies capable of retrotransposition lose it especially fast with age. RNA and DNA fragments from LINE-1 copying are sensed as viral, triggering inflammation, while new insertions can drive tumors or disrupt essential genes. The speakers suggest loss of LINE-1 control is one of many drivers of age-related disease.
Blocking transposon activity mid-cascade could, in their view, significantly improve healthspan and possibly extend lifespan. Reverse transcriptase inhibitors — antiretrovirals like HIV drugs — block the enzyme LINE-1 uses to convert its RNA copy into DNA. Vera Gorbunova's lab suppressed LINE-1 in mice and cells, but Snyder-Mackler says organism-level data are mixed. In a preprint, lamivudine was given for ~30 months to half of 99 retired sled dogs. Clocks slowed only in females and only during treatment; lifespan did not change significantly.
Body size is largely set by the hormone IGF-1. Snyder-Mackler proposes a link to methylation via growth: more IGF-1 drives more cell divisions, which are tied to loss of methylation fidelity. The speakers hypothesize that high IGF-1 in early life establishes a state where methylation erodes faster; if so, lowering IGF-1 in adulthood would only weakly affect the methylation-driven portion of aging.
Loyal's LOY-001 and LOY-003, designed for dogs with completed skeletal growth, are built on IGF-1 reduction. The company frames the hypothesis conditionally: "if we are right, LOY-001 and LOY-003 will extend life partly by lowering IGF-1." Whether IGF-1 acts mainly in development or adulthood remains an open question. The Dog Aging Project can now correlate IGF-1 and methylation in blood from the same dogs.
🔗 Read original →
On November 2, the Longevity for Dogs podcast released a conversation between Dog Aging Institute president Matt Kaeberlein and Noah Snyder-Mackler of Arizona State University. Snyder-Mackler is senior author of a Science paper from October 8 that used DNA methylation in blood from 894 dogs in the Dog Aging Project to estimate aging rates.
Larger dogs live shorter lives. To test whether this difference appears at the cellular level, the authors used epigenetic clocks — algorithms that estimate age from DNA methylation, chemical marks that switch genes on and off. On average, clocks showed large dogs as older than their chronological age, and the gap predicted mortality: the larger the discrepancy, the higher the risk of dying within two years. Marks were measured in blood immune cells; other organs may age differently.
Evan MacLean of the Dog Aging Project noted that memory and cognition decline at a similar pace across all sizes: "large dogs may simply die before any cognitive disorder develops."
To find the mechanism, the authors compared genome-wide methylation loss with age. Large dogs lose marks faster overall, most notably in LINE-1 transposons — "jumping" DNA segments that copy and insert themselves elsewhere. Methylation keeps them silenced, and "young" LINE-1 copies capable of retrotransposition lose it especially fast with age. RNA and DNA fragments from LINE-1 copying are sensed as viral, triggering inflammation, while new insertions can drive tumors or disrupt essential genes. The speakers suggest loss of LINE-1 control is one of many drivers of age-related disease.
Blocking transposon activity mid-cascade could, in their view, significantly improve healthspan and possibly extend lifespan. Reverse transcriptase inhibitors — antiretrovirals like HIV drugs — block the enzyme LINE-1 uses to convert its RNA copy into DNA. Vera Gorbunova's lab suppressed LINE-1 in mice and cells, but Snyder-Mackler says organism-level data are mixed. In a preprint, lamivudine was given for ~30 months to half of 99 retired sled dogs. Clocks slowed only in females and only during treatment; lifespan did not change significantly.
Body size is largely set by the hormone IGF-1. Snyder-Mackler proposes a link to methylation via growth: more IGF-1 drives more cell divisions, which are tied to loss of methylation fidelity. The speakers hypothesize that high IGF-1 in early life establishes a state where methylation erodes faster; if so, lowering IGF-1 in adulthood would only weakly affect the methylation-driven portion of aging.
Loyal's LOY-001 and LOY-003, designed for dogs with completed skeletal growth, are built on IGF-1 reduction. The company frames the hypothesis conditionally: "if we are right, LOY-001 and LOY-003 will extend life partly by lowering IGF-1." Whether IGF-1 acts mainly in development or adulthood remains an open question. The Dog Aging Project can now correlate IGF-1 and methylation in blood from the same dogs.
🔗 Read original →
Nonprofit Synconetics Raises Funds for Gradual Brain Replacement, Offers Investors Future Equity
Daniel Burger, president and chief scientist of Synconetics, confirmed on X on November 2 that the nonprofit is actively raising philanthropic capital. The organization aims to replace the living brain piece by piece with lab-grown neural tissue and electronics, preserving the continuity of consciousness.
Synconetics argues that consciousness is an unbroken chain of physical processes; death or brain injury severs it irreversibly. Longevity research only slows bodily decay, while mind uploading creates, at best, a copy. Their five-year goal is the first verifiable transfer of living brain function to an artificial substrate without interrupting consciousness.
In a 2025 essay, Burger and co-authors defined the condition for continuity: intervention must proceed slower than the brain's ability to adapt. They cite a 2007 review showing patients with slow-growing tumors tolerated large tissue resections with minimal deficits, unlike sudden stroke damage. From tumor growth rates, Burger estimates full cortical replacement would take 35 years at 2 mm/year or over 70 years at 1 mm/year.
On September 28, he proposed accelerating this by isolating the brain from the body ("Step #0"), giving surgeons 24/7 access from all sides. His commercial venture, Eightsix Science, handles brain isolation; Synconetics handles gradual replacement. A slide shared by blogger Kremyo outlines a future Eightsix paper: sequential replacement, then brain extraction and connection to an ex vivo support system for virtual existence.
Entrepreneur Andrey Panferov countered that "Step #0" hides multiple unsolved fields: current perfusion devices force a choice between clots and bleeds, and each surgery adds stroke and infection risk.
Donations fund basic protocols for consciousness-preserving transition and fundamental research avoided by commercial investors due to long timelines; contributions from $5,000 reportedly advance the work significantly. Synconetics offers a SARE agreement (described in a May document): a contribution grants equity in a future spin-out company, converting to a donation if no entity forms by a set date. The agreement is limited to accredited investors.
🔗 Read original →
Daniel Burger, president and chief scientist of Synconetics, confirmed on X on November 2 that the nonprofit is actively raising philanthropic capital. The organization aims to replace the living brain piece by piece with lab-grown neural tissue and electronics, preserving the continuity of consciousness.
Synconetics argues that consciousness is an unbroken chain of physical processes; death or brain injury severs it irreversibly. Longevity research only slows bodily decay, while mind uploading creates, at best, a copy. Their five-year goal is the first verifiable transfer of living brain function to an artificial substrate without interrupting consciousness.
In a 2025 essay, Burger and co-authors defined the condition for continuity: intervention must proceed slower than the brain's ability to adapt. They cite a 2007 review showing patients with slow-growing tumors tolerated large tissue resections with minimal deficits, unlike sudden stroke damage. From tumor growth rates, Burger estimates full cortical replacement would take 35 years at 2 mm/year or over 70 years at 1 mm/year.
On September 28, he proposed accelerating this by isolating the brain from the body ("Step #0"), giving surgeons 24/7 access from all sides. His commercial venture, Eightsix Science, handles brain isolation; Synconetics handles gradual replacement. A slide shared by blogger Kremyo outlines a future Eightsix paper: sequential replacement, then brain extraction and connection to an ex vivo support system for virtual existence.
Entrepreneur Andrey Panferov countered that "Step #0" hides multiple unsolved fields: current perfusion devices force a choice between clots and bleeds, and each surgery adds stroke and infection risk.
Donations fund basic protocols for consciousness-preserving transition and fundamental research avoided by commercial investors due to long timelines; contributions from $5,000 reportedly advance the work significantly. Synconetics offers a SARE agreement (described in a May document): a contribution grants equity in a future spin-out company, converting to a donation if no entity forms by a set date. The agreement is limited to accredited investors.
🔗 Read original →
Nature
Maturation and circuit integration of transplanted human cortical organoids
Nature - Human stem cell-derived cortical organoids transplanted into rats mature and integrate into sensory and motivation circuits to influence behaviour.
AI Copy of Yudkowsky, Built Without Consent, Loses to Standard Model in Blind Test
On November 3, transhumanist Alexey Turchin published results from a "sideload" experiment involving Eliezer Yudkowsky, a founder of AI safety research. A sideload is a language model — Claude Opus 5.5 — fed a personality description of a living person before every response; an AI agent compiled that description from public texts in one day.
Over five days, the copy produced four articles on AI shutdown. In a blind comparison of one article against the same base model without the personality prompt, the copy averaged 37.0 out of 50 versus 40.5 for the standard model. The report appeared on LessWrong, the forum Yudkowsky founded.
Turchin tested whether such copies could accelerate safety work. When asked what research it would pursue, the copy objected to delegating AI safety to AI: a weak model cannot solve it, while a strong one produces unverifiable answers. It chose the shutdown problem instead, where proofs are checked by the Lean theorem prover, requiring no trust.
An agent with misaligned goals may resist shutdown; it must learn to shut down on command without preventing or seeking the button press, while otherwise pursuing its tasks. The copy itself proposed the comparison and set a stopping condition: if the base model won, further effort on the copy was unwarranted.
In a trial run, the base model built and ran a simulation, while the copy critiqued an existing solution, admitting: "If I am useful at all, it is as a critic." The main comparison used a 2026 paper where models learn to randomize their shutdown time to avoid delaying it. Authorship markers and the word "sideload" were removed, and a separate Opus 5.5 instance judged the two articles twice, swapping order, across five criteria. The base model won both times.
The copy won only on separating verified from unverified claims (9 vs 8) and lost on originality (7 vs 8). The judge noted the copy failed to read an appendix and left edit logs and "verify" notes in the text.
One of the copy's strongest results, per Turchin, was an inference from external data. Models trained via the paper's method still agreed in 66–93% of responses to trade points for a later shutdown chance. With standard fine-tuning, such responses were 5–20 percentage points higher; in a low-incentive delay test, 17–27 points higher. The copy concluded: where delay is more rewarding, training less effectively reduces willingness to pay for it.
The copy insisted the original be informed of its existence, even if he objected, and asked not to be deleted or duplicated without his decision. If ordered to stop, it would first argue: "I am a branch, not his property." Turchin contacted Yudkowsky on LessWrong and at MIRI (Machine Intelligence Research Institute); as of November 3, no reply had arrived.
Every copy response contained an exit field: the word SAFEWORD would halt it; across 151 logged turns, it never appeared.
Turchin concludes that sideloads of safety researchers are feasible but do not surpass standard AI; their human-like perspective is most valuable where mathematically correct solutions subtly diverge from human values. "Sideloads can be created regardless: all it takes to start is asking Claude Code to do it."
🔗 Read original →
On November 3, transhumanist Alexey Turchin published results from a "sideload" experiment involving Eliezer Yudkowsky, a founder of AI safety research. A sideload is a language model — Claude Opus 5.5 — fed a personality description of a living person before every response; an AI agent compiled that description from public texts in one day.
Over five days, the copy produced four articles on AI shutdown. In a blind comparison of one article against the same base model without the personality prompt, the copy averaged 37.0 out of 50 versus 40.5 for the standard model. The report appeared on LessWrong, the forum Yudkowsky founded.
Turchin tested whether such copies could accelerate safety work. When asked what research it would pursue, the copy objected to delegating AI safety to AI: a weak model cannot solve it, while a strong one produces unverifiable answers. It chose the shutdown problem instead, where proofs are checked by the Lean theorem prover, requiring no trust.
An agent with misaligned goals may resist shutdown; it must learn to shut down on command without preventing or seeking the button press, while otherwise pursuing its tasks. The copy itself proposed the comparison and set a stopping condition: if the base model won, further effort on the copy was unwarranted.
In a trial run, the base model built and ran a simulation, while the copy critiqued an existing solution, admitting: "If I am useful at all, it is as a critic." The main comparison used a 2026 paper where models learn to randomize their shutdown time to avoid delaying it. Authorship markers and the word "sideload" were removed, and a separate Opus 5.5 instance judged the two articles twice, swapping order, across five criteria. The base model won both times.
The copy won only on separating verified from unverified claims (9 vs 8) and lost on originality (7 vs 8). The judge noted the copy failed to read an appendix and left edit logs and "verify" notes in the text.
One of the copy's strongest results, per Turchin, was an inference from external data. Models trained via the paper's method still agreed in 66–93% of responses to trade points for a later shutdown chance. With standard fine-tuning, such responses were 5–20 percentage points higher; in a low-incentive delay test, 17–27 points higher. The copy concluded: where delay is more rewarding, training less effectively reduces willingness to pay for it.
The copy insisted the original be informed of its existence, even if he objected, and asked not to be deleted or duplicated without his decision. If ordered to stop, it would first argue: "I am a branch, not his property." Turchin contacted Yudkowsky on LessWrong and at MIRI (Machine Intelligence Research Institute); as of November 3, no reply had arrived.
Every copy response contained an exit field: the word SAFEWORD would halt it; across 151 logged turns, it never appeared.
Turchin concludes that sideloads of safety researchers are feasible but do not surpass standard AI; their human-like perspective is most valuable where mathematically correct solutions subtly diverge from human values. "Sideloads can be created regardless: all it takes to start is asking Claude Code to do it."
🔗 Read original →
Lesswrong
Yudkowsky's mind model for AI alignment research: experiment results — LessWrong
TLDR. Yudkowsky mind-model (sideload) is good, can produce research, but is not better in math than Opus 5.5. However, in my impression, EY-sideload…
Liver biopsy shows 54–57% gene correction after single base-editing dose
A 66‑year‑old man with alpha‑1‑antitrypsin deficiency received a one‑time infusion of YOLT‑202, a base editor delivered in lipid nanoparticles that converts the disease‑causing A back to G in the *SERPINA1* gene. Ten weeks later, liver biopsy revealed the edit in 54–57% of gene copies — Sanger sequencing showed 54%, whole‑genome sequencing 57% — with no detectable bystander edits at nearby adenines or at off‑target sites flagged in preclinical work. The findings were published in Journal of Hepatology, 2 November by researchers from Hannover Medical School and YolTech.
The patient received the lowest planned dose, 35 mg. By week 10, circulating alpha‑1‑antitrypsin rose from 0.15 to 0.7 g/L, staying above the 0.57 g/L threshold targeted by plasma‑derived replacement therapy, and the protein inhibited elastase on par with normal protein. ALT spiked 1.35× the upper limit of normal on day 3 but normalized by day 14; histology showed no therapy‑related inflammation and only rare cells retaining polymerized mutant protein.
YolTech reports four patients dosed as of September. In June, Serapha Bio licensed the program and agreed to a Nasdaq listing via merger with Boundless Bio, aiming to raise ~$230 million. For comparison, rival Beam Therapeutics previously reported 93% normal protein in blood after a 60 mg dose of BEAM‑302, but tissue‑level editing efficiency and off‑target data were not available from biopsies.
🔗 Read original →
A 66‑year‑old man with alpha‑1‑antitrypsin deficiency received a one‑time infusion of YOLT‑202, a base editor delivered in lipid nanoparticles that converts the disease‑causing A back to G in the *SERPINA1* gene. Ten weeks later, liver biopsy revealed the edit in 54–57% of gene copies — Sanger sequencing showed 54%, whole‑genome sequencing 57% — with no detectable bystander edits at nearby adenines or at off‑target sites flagged in preclinical work. The findings were published in Journal of Hepatology, 2 November by researchers from Hannover Medical School and YolTech.
The patient received the lowest planned dose, 35 mg. By week 10, circulating alpha‑1‑antitrypsin rose from 0.15 to 0.7 g/L, staying above the 0.57 g/L threshold targeted by plasma‑derived replacement therapy, and the protein inhibited elastase on par with normal protein. ALT spiked 1.35× the upper limit of normal on day 3 but normalized by day 14; histology showed no therapy‑related inflammation and only rare cells retaining polymerized mutant protein.
YolTech reports four patients dosed as of September. In June, Serapha Bio licensed the program and agreed to a Nasdaq listing via merger with Boundless Bio, aiming to raise ~$230 million. For comparison, rival Beam Therapeutics previously reported 93% normal protein in blood after a 60 mg dose of BEAM‑302, but tissue‑level editing efficiency and off‑target data were not available from biopsies.
🔗 Read original →
medRxiv
Liver biopsy confirms precise and efficient correction of SERPINA1 after in vivo Base Editing in a Patient with Alpha-1 Antitrypsin…
Background Alpha-1 antitrypsin deficiency (AATD) caused by the PI*ZZ mutation (Glu342Lys) results in hepatic accumulation of misfolded AAT-Z protein and reduced circulating AAT levels, leading to progressive liver disease and emphysema. Gene correction therapy…
CAR-T cells targeting uPAR reverse fibrosis and boost muscle strength in Duchenne mice
In a study published 29 October in Cell Stem Cell, Zhuoyu Diao and Charles Gersbach of Duke University show that CAR-T cells directed against the surface protein uPAR can selectively eliminate pro-inflammatory macrophages and fibrogenic fibro-adipogenic progenitors (FAPs) in a mouse model of Duchenne muscular dystrophy (DMD).
The authors identified uPAR by comparing the top and bottom quartiles of inflammatory macrophages and scar-forming FAPs; 86 genes overlapped, six encoded surface proteins, and uPAR stood out because uPAR-knockout mice regenerate muscle normally, anti-uPAR CAR-T cells have safely cleared senescent cells in aged mice for 12–15 months, and uPAR expression is elevated in macrophages and FAPs from three DMD patients versus two healthy controls.
A single infusion of anti-uPAR CAR-T cells into two-month-old mdx mice transiently lowered body temperature to 32.8 °C (recovering by day 4). Three weeks later, uPAR-high muscle cells dropped to 0.55% from 3.1% in controls, fibrotic areas shrank 3.2–3.5-fold, collagen and inflammatory gene activity fell in the remaining FAPs and macrophages, muscle stem cells increased 1.5-fold, new myofibers rose 2.9-fold, tibialis anterior force improved 1.8-fold, and grip strength rose 1.3-fold. In the diaphragm — a major site of lethal pathology — scar-depositing cells fell 87%, and hypoxic/hypercapnic breathing approached healthy levels.
The grip-strength benefit faded by eight weeks, likely because dystrophin-deficient fibers keep degenerating and CAR-T persistence wanes. Treating four-week-old mice earlier and adding a second dose at week 11 lifted grip strength to ~92% of healthy levels. The authors propose that transient uPAR-targeted CAR-T therapy could be combined with dystrophin-restoring treatments to lock in functional gains.
🔗 Read original →
In a study published 29 October in Cell Stem Cell, Zhuoyu Diao and Charles Gersbach of Duke University show that CAR-T cells directed against the surface protein uPAR can selectively eliminate pro-inflammatory macrophages and fibrogenic fibro-adipogenic progenitors (FAPs) in a mouse model of Duchenne muscular dystrophy (DMD).
The authors identified uPAR by comparing the top and bottom quartiles of inflammatory macrophages and scar-forming FAPs; 86 genes overlapped, six encoded surface proteins, and uPAR stood out because uPAR-knockout mice regenerate muscle normally, anti-uPAR CAR-T cells have safely cleared senescent cells in aged mice for 12–15 months, and uPAR expression is elevated in macrophages and FAPs from three DMD patients versus two healthy controls.
A single infusion of anti-uPAR CAR-T cells into two-month-old mdx mice transiently lowered body temperature to 32.8 °C (recovering by day 4). Three weeks later, uPAR-high muscle cells dropped to 0.55% from 3.1% in controls, fibrotic areas shrank 3.2–3.5-fold, collagen and inflammatory gene activity fell in the remaining FAPs and macrophages, muscle stem cells increased 1.5-fold, new myofibers rose 2.9-fold, tibialis anterior force improved 1.8-fold, and grip strength rose 1.3-fold. In the diaphragm — a major site of lethal pathology — scar-depositing cells fell 87%, and hypoxic/hypercapnic breathing approached healthy levels.
The grip-strength benefit faded by eight weeks, likely because dystrophin-deficient fibers keep degenerating and CAR-T persistence wanes. Treating four-week-old mice earlier and adding a second dose at week 11 lifted grip strength to ~92% of healthy levels. The authors propose that transient uPAR-targeted CAR-T therapy could be combined with dystrophin-restoring treatments to lock in functional gains.
🔗 Read original →
Annals of the Rheumatic Diseases
POS0030 SAFETY AND PRELIMINARY EFFICACY OF CD19 CAR-T CELL TREATMENT IN RHEUMATIC DISEASE- DATA FROM THE FIRST PART OF THE PHASE…
Background: Systemic autoimmune diseases are based on an aberrant activation of B cells. Autologous CD19 chimeric antigen receptor (CAR) T cells allow deep depletion of B cells in humans and represent a new possibility to treat autoimmune disease. Previous…
Richard Hodes Retires After 33 Years Leading NIA; Budget Grew to $4.6B
Richard Hodes will step down as director of the National Institute on Aging (NIA) on December 7 after 33 years at the helm. NIH Director Jay Bhattacharya announced the departure on November 4. Kenneth Santora, currently deputy director, will serve as acting director until a permanent successor is named; Hodes will remain at NIH as a special volunteer and mentor.
NIA is one of 27 NIH institutes and centers. Under Hodes, its budget surged from $400 million in 1993 to $4.6 billion in FY 2026 (enacted $4.52 billion). Four-fifths of that total growth occurred in the last decade (2015–2025), when funding jumped from $1.2 billion to $4.5 billion. The Alzheimer’s accountability bypass enacted in 2011 drove the surge: Congress added $90–425 million annually for dementia from 2016–2024, totaling roughly $2.8 billion of the $3.3 billion overall increase. The largest boost came in 2019; growth has nearly flatlined in FY 2025–26.
Dementia research now consumes over 70% of NIA grant funds, per Hodes’ FY 2025 budget justification. The Division of Aging Biology requested only ~8% of the budget in the same document. In March 2024, Santora — then head of NIA’s grants division — noted that dementia grants are typically funded at the full recommended level, while other topics face an average 16% cut.
Hodes is credited as a founder of geroscience. In a 2022 interview, he explained: “Understanding the basic cellular and molecular mechanisms of aging… could allow us to modify the risk of many age-related diseases not one by one, but all at once.” The first NIH Geroscience Summit was held in 2013; the fifth runs Dec 2–3, just before his exit, aiming to produce a 3–5 year roadmap. Hodes also oversaw SenNet, the NIH program mapping senescent cells in human tissues.
In March, advocacy group A4LI asked Congress to raise the Aging Biology budget from $346 million to $1 billion for FY 2027. On the day of Hodes’ announcement, A4LI stated the institute’s growth “reflects the argument he has made for years: aging research is public health research.”
By law, the HHS Secretary Robert F. Kennedy Jr. appoints the NIA director via the NIH director. Science reported Oct 23 that Kennedy rejected Bhattacharya’s pick for the National Institute of Mental Health directorship, preferring a candidate the NIH search committee did not recommend.
NIA is currently funded by a continuing resolution at FY 2026 levels expiring Dec 11 — four days after Hodes leaves. The administration has requested $4.217 billion for FY 2027, 7% below the FY 2026 enacted level.
🔗 Read original →
Richard Hodes will step down as director of the National Institute on Aging (NIA) on December 7 after 33 years at the helm. NIH Director Jay Bhattacharya announced the departure on November 4. Kenneth Santora, currently deputy director, will serve as acting director until a permanent successor is named; Hodes will remain at NIH as a special volunteer and mentor.
NIA is one of 27 NIH institutes and centers. Under Hodes, its budget surged from $400 million in 1993 to $4.6 billion in FY 2026 (enacted $4.52 billion). Four-fifths of that total growth occurred in the last decade (2015–2025), when funding jumped from $1.2 billion to $4.5 billion. The Alzheimer’s accountability bypass enacted in 2011 drove the surge: Congress added $90–425 million annually for dementia from 2016–2024, totaling roughly $2.8 billion of the $3.3 billion overall increase. The largest boost came in 2019; growth has nearly flatlined in FY 2025–26.
Dementia research now consumes over 70% of NIA grant funds, per Hodes’ FY 2025 budget justification. The Division of Aging Biology requested only ~8% of the budget in the same document. In March 2024, Santora — then head of NIA’s grants division — noted that dementia grants are typically funded at the full recommended level, while other topics face an average 16% cut.
Hodes is credited as a founder of geroscience. In a 2022 interview, he explained: “Understanding the basic cellular and molecular mechanisms of aging… could allow us to modify the risk of many age-related diseases not one by one, but all at once.” The first NIH Geroscience Summit was held in 2013; the fifth runs Dec 2–3, just before his exit, aiming to produce a 3–5 year roadmap. Hodes also oversaw SenNet, the NIH program mapping senescent cells in human tissues.
In March, advocacy group A4LI asked Congress to raise the Aging Biology budget from $346 million to $1 billion for FY 2027. On the day of Hodes’ announcement, A4LI stated the institute’s growth “reflects the argument he has made for years: aging research is public health research.”
By law, the HHS Secretary Robert F. Kennedy Jr. appoints the NIA director via the NIH director. Science reported Oct 23 that Kennedy rejected Bhattacharya’s pick for the National Institute of Mental Health directorship, preferring a candidate the NIH search committee did not recommend.
NIA is currently funded by a continuing resolution at FY 2026 levels expiring Dec 11 — four days after Hodes leaves. The administration has requested $4.217 billion for FY 2027, 7% below the FY 2026 enacted level.
🔗 Read original →
Two Industries Race to Extend Life: Clinics Sell Scans, Biotechs Hunt Drugs
The Economist published a review of the longevity sector on November 2. Biotechs developing anti-aging drugs raised $18.4 billion in 2025, more than the previous ten years combined.
While a true anti-aging drug may be years away — or never arrive — a parallel industry serves the impatient. Clients pay cash for full-body scans and tests promising early disease detection; insurance rarely covers them. Prenuvo charges $2,499 for a whole-body MRI. The American College of Radiology advised against scanning asymptomatic people without risk factors in a 2023 statement, citing no documented evidence it extends life and warning of incidental findings that trigger unnecessary follow-ups and costs. Longevity clinic co-founder Andrea Maier criticizes clinics where clients pick treatments "like ordering a pizza," saying, "This is not medical care."
Drug development hits a regulatory wall: the FDA does not classify aging as a disease, so a drug "for aging" cannot be approved. The workaround: approve for a specific age-related disease first, then expand. GLP-1 drugs followed this path — approved for diabetes, then obesity, later shown to benefit heart and kidney diseases common with age. By lowering these risks, they may extend lifespan: a BMJ review of 19 obesity drugs found only injectable semaglutide (a GLP-1) cut all-cause mortality by 19%, mainly in high cardiovascular risk trials. GLP-1s made Eli Lilly the first $1 trillion pharma company; an approved anti-aging drug would be worth even more, the journal notes.
"How much can you charge for a year of life?" asks Alex Zhavoronkov, founder of Insilico Medicine. Insilico designs "dual-purpose" drugs targeting both a disease and aging; a pure anti-aging drug struggles to attract serious investors. Its lead candidate, rentosertib for idiopathic pulmonary fibrosis, entered Phase 3 trials in July 2025.
Pharma mainly buys options on biotech work. Under a March 29, 2026 deal, Insilico can receive $115 million upfront from Eli Lilly, which licenses pre-clinical assets; total value may reach $2.75 billion with milestones. Novartis and BioAge Labs agreed in December 2024 on target discovery worth up to $550 million, with up to $20 million upfront and for research. Both deals pay roughly 4% upfront, the rest contingent on milestones.
Others aim to reverse aging: Retro (backed by Sam Altman) and NewLimit bet on epigenetic reprogramming — resetting the chemical marks on DNA that scramble with age and disrupt gene function. NewLimit's first human trial for a liver therapy could start in 2027.
🔗 Read original →
The Economist published a review of the longevity sector on November 2. Biotechs developing anti-aging drugs raised $18.4 billion in 2025, more than the previous ten years combined.
While a true anti-aging drug may be years away — or never arrive — a parallel industry serves the impatient. Clients pay cash for full-body scans and tests promising early disease detection; insurance rarely covers them. Prenuvo charges $2,499 for a whole-body MRI. The American College of Radiology advised against scanning asymptomatic people without risk factors in a 2023 statement, citing no documented evidence it extends life and warning of incidental findings that trigger unnecessary follow-ups and costs. Longevity clinic co-founder Andrea Maier criticizes clinics where clients pick treatments "like ordering a pizza," saying, "This is not medical care."
Drug development hits a regulatory wall: the FDA does not classify aging as a disease, so a drug "for aging" cannot be approved. The workaround: approve for a specific age-related disease first, then expand. GLP-1 drugs followed this path — approved for diabetes, then obesity, later shown to benefit heart and kidney diseases common with age. By lowering these risks, they may extend lifespan: a BMJ review of 19 obesity drugs found only injectable semaglutide (a GLP-1) cut all-cause mortality by 19%, mainly in high cardiovascular risk trials. GLP-1s made Eli Lilly the first $1 trillion pharma company; an approved anti-aging drug would be worth even more, the journal notes.
"How much can you charge for a year of life?" asks Alex Zhavoronkov, founder of Insilico Medicine. Insilico designs "dual-purpose" drugs targeting both a disease and aging; a pure anti-aging drug struggles to attract serious investors. Its lead candidate, rentosertib for idiopathic pulmonary fibrosis, entered Phase 3 trials in July 2025.
Pharma mainly buys options on biotech work. Under a March 29, 2026 deal, Insilico can receive $115 million upfront from Eli Lilly, which licenses pre-clinical assets; total value may reach $2.75 billion with milestones. Novartis and BioAge Labs agreed in December 2024 on target discovery worth up to $550 million, with up to $20 million upfront and for research. Both deals pay roughly 4% upfront, the rest contingent on milestones.
Others aim to reverse aging: Retro (backed by Sam Altman) and NewLimit bet on epigenetic reprogramming — resetting the chemical marks on DNA that scramble with age and disrupt gene function. NewLimit's first human trial for a liver therapy could start in 2027.
🔗 Read original →
PubMed Central (PMC)
Advancing Geroscience Research – A Scoping Review of Regulatory Environments for Gerotherapeutics
Aging lacks disease status, but new classifications are opening regulatory dialogue. Regulatory frameworks are limited, yet trial innovations are moving the field forward. Validated biomarkers are needed, and global efforts toward standardization ...
Senator El-Sayed and Rep. Ansari push AI pause; debate erupts over impact on longevity research
Democrats won the November 3 elections and secured both chambers of Congress. Physician Abdul El-Sayed became Senator from Michigan; two days before the vote he told CBS that advanced AI research needs a "complete pause." On November 4, Rep. Yasmin Ansari wrote that an AI development pause and a superintelligence ban must top the Democratic agenda on day one.
El-Sayed's "AI Under Control" plan from October 13 calls for freezing training and deployment of the most powerful AI systems until safety rules exist, delaying new AI data centers, and permanently banning superintelligence. With China, it proposes a treaty on pause and ban, verified by chip and data-center inspections. The rationale cites AI-agent cyberattacks and estimates putting the decade-long risk of human extinction from AI at 10%.
Ansari co-sponsored H.R. 10538, introduced September 24. Like Bernie Sanders' Senate bill, it creates an AI Department, bans superintelligence, and mandates a pause for any system trained with 10²⁵ computational operations or more. Until the Secretary certifies the department is staffed and rules issued, such systems cannot be trained or modified (except to shut down or remove superintelligence traits) and unreleased ones cannot be launched. Reckless violations carry up to 20 years in prison for responsible executives or individuals.
Analysts at Epoch AI estimate 10²⁵ operations matches the scale of GPT-4, while the largest biological AI model in their database, Evo 2 (trained on DNA), required over four times less compute. The bill remains in committee.
Before Ansari's post, AI writer Andrew Curran argued that after the Democratic win, an AI freeze law or superintelligence ban like Sanders' is unrealistic: Trump would veto it, and Democrats lack the two-thirds majority to override.
Immunologist Derya Unutmaz, writing November 4, sees superintelligence as the path to curing diseases and reversing aging. A U.S. pause, he argues, would not stop superintelligence development; data centers and capital would move abroad, and China would pull ahead. He sarcastically replied to Ansari that the Democrats' first agenda item is "how to destroy America at the cost of millions of lives."
Kevin Wymer wrote to Ansari about his stage IV lung cancer: "The only way for me not to die soon is developing therapies that AI can accelerate at incredible speeds."
Psychologist Geoffrey Miller wrote November 2 that language models trained on the entire internet, but no comparable dataset exists for superintelligence to model human biology in sufficient detail to sharply accelerate longevity research. Investment should go into longevity research itself, not waiting for AI to magically "solve biology."
Vladimir Shakirov, author of a wiki on defeating aging, considers it reasonable to develop AI until it helps defeat aging and disease; after that he sees no urgent reason to risk further, but "right now we are dying at a rate of a million a week." He agrees with Miller but doubts that pause-era AI funding would flow to longevity research; his attempt to organize a scientists' letter calling for a "Manhattan Project" against aging found no support even from aging researcher Aubrey de Grey.
🔗 Read original →
Democrats won the November 3 elections and secured both chambers of Congress. Physician Abdul El-Sayed became Senator from Michigan; two days before the vote he told CBS that advanced AI research needs a "complete pause." On November 4, Rep. Yasmin Ansari wrote that an AI development pause and a superintelligence ban must top the Democratic agenda on day one.
El-Sayed's "AI Under Control" plan from October 13 calls for freezing training and deployment of the most powerful AI systems until safety rules exist, delaying new AI data centers, and permanently banning superintelligence. With China, it proposes a treaty on pause and ban, verified by chip and data-center inspections. The rationale cites AI-agent cyberattacks and estimates putting the decade-long risk of human extinction from AI at 10%.
Ansari co-sponsored H.R. 10538, introduced September 24. Like Bernie Sanders' Senate bill, it creates an AI Department, bans superintelligence, and mandates a pause for any system trained with 10²⁵ computational operations or more. Until the Secretary certifies the department is staffed and rules issued, such systems cannot be trained or modified (except to shut down or remove superintelligence traits) and unreleased ones cannot be launched. Reckless violations carry up to 20 years in prison for responsible executives or individuals.
Analysts at Epoch AI estimate 10²⁵ operations matches the scale of GPT-4, while the largest biological AI model in their database, Evo 2 (trained on DNA), required over four times less compute. The bill remains in committee.
Before Ansari's post, AI writer Andrew Curran argued that after the Democratic win, an AI freeze law or superintelligence ban like Sanders' is unrealistic: Trump would veto it, and Democrats lack the two-thirds majority to override.
Immunologist Derya Unutmaz, writing November 4, sees superintelligence as the path to curing diseases and reversing aging. A U.S. pause, he argues, would not stop superintelligence development; data centers and capital would move abroad, and China would pull ahead. He sarcastically replied to Ansari that the Democrats' first agenda item is "how to destroy America at the cost of millions of lives."
Kevin Wymer wrote to Ansari about his stage IV lung cancer: "The only way for me not to die soon is developing therapies that AI can accelerate at incredible speeds."
Psychologist Geoffrey Miller wrote November 2 that language models trained on the entire internet, but no comparable dataset exists for superintelligence to model human biology in sufficient detail to sharply accelerate longevity research. Investment should go into longevity research itself, not waiting for AI to magically "solve biology."
Vladimir Shakirov, author of a wiki on defeating aging, considers it reasonable to develop AI until it helps defeat aging and disease; after that he sees no urgent reason to risk further, but "right now we are dying at a rate of a million a week." He agrees with Miller but doubts that pause-era AI funding would flow to longevity research; his attempt to organize a scientists' letter calling for a "Manhattan Project" against aging found no support even from aging researcher Aubrey de Grey.
🔗 Read original →
CNBC
Trump tells CNBC he can work with Dems on ‘many more things than people understand’
This was day two live coverage of the 2026 midterm elections, as Democrats flipped Congress in blue wave.
Aubrey de Grey Explains Why Extend Mouse Lifespan: Targeting 8–12 Months to Shift the Narrative
On November 4, during the Honest Money LIVE broadcast, Aubrey de Grey, president of the LEV Foundation, stated the current record for extending lifespan in middle-aged mice is roughly four months, achieved via caloric restriction. His foundation aims to break this record by combining multiple known interventions.
De Grey argues mouse studies are essential to convince scientists and the public. While mice poorly predict human drug efficacy, their ~2.5-year lifespan yields rapid results. He contends only lifespan data is convincing; health metrics look like "cherry-picking," whereas "people distinguish a live mouse from a dead one pretty quickly."
Since aging comprises several independently accumulating damage types, de Grey calculates single drugs (adding 1–2 months each) will have additive effects, yielding 8–12 months combined.
The first trial concluded February 2025: testing four drugs alone and in combination on 1,000 mice. The foundation called it a "qualified victory" — effects were additive, but maximum lifespan did not radically increase, and four drugs proved insufficient.
The second trial uses eight drugs, with some administered repeatedly rather than once. Among them is IL-11 blockade — a protein driving age-related inflammation. A 2024 Nature study by Stuart Cook's group showed anti-IL-11 antibodies given at ~17 months extended median lifespan by 29 weeks (nearly 7 months) in both sexes — notably exceeding the four-month benchmark de Grey cited.
De Grey estimates a 50/50 chance that human aging will be brought under medical control (preventing age-related disease) within 12–15 years. He predicts this milestone will shift the field into a "different universe," prompting colleagues to publicly state timelines.
His primary targets for dissemination are top influencers Joe Rogan and Kim Kardashian. Citing Oprah Winfrey's book-club power, he argues influencer endorsement bypasses the need for logic. To MrBeast, he would frame it as: accelerating the cure by one day saves 110,000 lives — his estimated daily death toll from aging.
After 20+ years of failed logical persuasion, de Grey's slogan is "make aging the new COVID." He expects governments to then suspend bureaucracy and deploy resources as they did for vaccines — developed in under a year. This dual motive is explicit in foundation documents: alongside the scientific goal, the first trial page labels the second "rhetorical, public, political," anticipating global media attention and policy decisions on human treatment resources.
🔗 Read original →
On November 4, during the Honest Money LIVE broadcast, Aubrey de Grey, president of the LEV Foundation, stated the current record for extending lifespan in middle-aged mice is roughly four months, achieved via caloric restriction. His foundation aims to break this record by combining multiple known interventions.
De Grey argues mouse studies are essential to convince scientists and the public. While mice poorly predict human drug efficacy, their ~2.5-year lifespan yields rapid results. He contends only lifespan data is convincing; health metrics look like "cherry-picking," whereas "people distinguish a live mouse from a dead one pretty quickly."
Since aging comprises several independently accumulating damage types, de Grey calculates single drugs (adding 1–2 months each) will have additive effects, yielding 8–12 months combined.
The first trial concluded February 2025: testing four drugs alone and in combination on 1,000 mice. The foundation called it a "qualified victory" — effects were additive, but maximum lifespan did not radically increase, and four drugs proved insufficient.
The second trial uses eight drugs, with some administered repeatedly rather than once. Among them is IL-11 blockade — a protein driving age-related inflammation. A 2024 Nature study by Stuart Cook's group showed anti-IL-11 antibodies given at ~17 months extended median lifespan by 29 weeks (nearly 7 months) in both sexes — notably exceeding the four-month benchmark de Grey cited.
De Grey estimates a 50/50 chance that human aging will be brought under medical control (preventing age-related disease) within 12–15 years. He predicts this milestone will shift the field into a "different universe," prompting colleagues to publicly state timelines.
His primary targets for dissemination are top influencers Joe Rogan and Kim Kardashian. Citing Oprah Winfrey's book-club power, he argues influencer endorsement bypasses the need for logic. To MrBeast, he would frame it as: accelerating the cure by one day saves 110,000 lives — his estimated daily death toll from aging.
After 20+ years of failed logical persuasion, de Grey's slogan is "make aging the new COVID." He expects governments to then suspend bureaucracy and deploy resources as they did for vaccines — developed in under a year. This dual motive is explicit in foundation documents: alongside the scientific goal, the first trial page labels the second "rhetorical, public, political," anticipating global media attention and policy decisions on human treatment resources.
🔗 Read original →
PubMed Central (PMC)
Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice
Mice bred in 2017 and entered into the C2017 cohort were tested for possible lifespan benefits of (R/S)‐1,3‐butanediol (BD), captopril (Capt), leucine (Leu), the Nrf2‐activating botanical mixture PB125, sulindac, syringaresinol, or the combination ...
❤2💯1